Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
Abstract Background Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients...
Saved in:
Published in | International journal of cardiology Vol. 150; no. 1; pp. 39 - 44 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Shannon
Elsevier Ireland Ltd
01.07.2011
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Background Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. We evaluated the stability of platelet inhibition following once-daily enteric-coated aspirin administration. Methods Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24 h after observed ingestion of 80-mg enteric-coated aspirin. Inhibition of the COX pathway was measured pharmacologically through plasma thromboxane (Tx) B2 levels, and functionally by light transmission aggregometry in response to arachidonic acid. COX-independent platelet activity was measured in response to adenosine diphosphate, epinephrine and collagen. Results Plasma TxB2 levels showed profound inhibition of TxA2 formation, which was stable throughout 24 h, in all but 1 subject. This subject had optimal response to aspirin (inhibition of platelet TxA2 production within 1 h), but recovered the ability to synthesize TxA2 within 24 h of aspirin ingestion. Arachidonic acid-induced platelet aggregation closely mirrored TxB2 formation in this patient, portraying a functional ability of the platelet to aggregate within 24 h of aspirin ingestion. COX-independent platelet aggregation triggered TxA2 production to a similar extent in all patients, likely through signal-dependent protein synthesis. Conclusions COX-dependent platelet activity is recovered in certain individuals within 24 h of aspirin administration. Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects. |
---|---|
AbstractList | Platelets, long believed to be incapable of
de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. We evaluated the stability of platelet inhibition following once-daily enteric-coated aspirin administration.
Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24
h after observed ingestion of 80-mg enteric-coated aspirin. Inhibition of the COX pathway was measured pharmacologically through plasma thromboxane (Tx) B
2 levels, and functionally by light transmission aggregometry in response to arachidonic acid. COX-independent platelet activity was measured in response to adenosine diphosphate, epinephrine and collagen.
Plasma TxB
2 levels showed profound inhibition of TxA
2 formation, which was stable throughout 24
h, in all but 1 subject. This subject had optimal response to aspirin (inhibition of platelet TxA
2 production within 1
h), but recovered the ability to synthesize TxA
2 within 24
h of aspirin ingestion. Arachidonic acid-induced platelet aggregation closely mirrored TxB
2 formation in this patient, portraying a functional ability of the platelet to aggregate within 24
h of aspirin ingestion. COX-independent platelet aggregation triggered TxA
2 production to a similar extent in all patients, likely through signal-dependent protein synthesis.
COX-dependent platelet activity is recovered in certain individuals within 24
h of aspirin administration. Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects. Abstract Background Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. We evaluated the stability of platelet inhibition following once-daily enteric-coated aspirin administration. Methods Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24 h after observed ingestion of 80-mg enteric-coated aspirin. Inhibition of the COX pathway was measured pharmacologically through plasma thromboxane (Tx) B2 levels, and functionally by light transmission aggregometry in response to arachidonic acid. COX-independent platelet activity was measured in response to adenosine diphosphate, epinephrine and collagen. Results Plasma TxB2 levels showed profound inhibition of TxA2 formation, which was stable throughout 24 h, in all but 1 subject. This subject had optimal response to aspirin (inhibition of platelet TxA2 production within 1 h), but recovered the ability to synthesize TxA2 within 24 h of aspirin ingestion. Arachidonic acid-induced platelet aggregation closely mirrored TxB2 formation in this patient, portraying a functional ability of the platelet to aggregate within 24 h of aspirin ingestion. COX-independent platelet aggregation triggered TxA2 production to a similar extent in all patients, likely through signal-dependent protein synthesis. Conclusions COX-dependent platelet activity is recovered in certain individuals within 24 h of aspirin administration. Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects. Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. We evaluated the stability of platelet inhibition following once-daily enteric-coated aspirin administration. Platelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24h after observed ingestion of 80-mg enteric-coated aspirin. Inhibition of the COX pathway was measured pharmacologically through plasma thromboxane (Tx) B(2) levels, and functionally by light transmission aggregometry in response to arachidonic acid. COX-independent platelet activity was measured in response to adenosine diphosphate, epinephrine and collagen. Plasma TxB(2) levels showed profound inhibition of TxA(2) formation, which was stable throughout 24h, in all but 1 subject. This subject had optimal response to aspirin (inhibition of platelet TxA(2) production within 1h), but recovered the ability to synthesize TxA(2) within 24h of aspirin ingestion. Arachidonic acid-induced platelet aggregation closely mirrored TxB(2) formation in this patient, portraying a functional ability of the platelet to aggregate within 24h of aspirin ingestion. COX-independent platelet aggregation triggered TxA(2) production to a similar extent in all patients, likely through signal-dependent protein synthesis. COX-dependent platelet activity is recovered in certain individuals within 24h of aspirin administration. Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects. BACKGROUNDPlatelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been inactivated by aspirin. This may explain the inefficacy of the drug to induce sustained platelet inhibition in certain patients. We evaluated the stability of platelet inhibition following once-daily enteric-coated aspirin administration.METHODSPlatelet responsiveness to aspirin was evaluated in 11 stable coronary artery disease patients on chronic aspirin therapy before and 1, 3, 8, and 24h after observed ingestion of 80-mg enteric-coated aspirin. Inhibition of the COX pathway was measured pharmacologically through plasma thromboxane (Tx) B(2) levels, and functionally by light transmission aggregometry in response to arachidonic acid. COX-independent platelet activity was measured in response to adenosine diphosphate, epinephrine and collagen.RESULTSPlasma TxB(2) levels showed profound inhibition of TxA(2) formation, which was stable throughout 24h, in all but 1 subject. This subject had optimal response to aspirin (inhibition of platelet TxA(2) production within 1h), but recovered the ability to synthesize TxA(2) within 24h of aspirin ingestion. Arachidonic acid-induced platelet aggregation closely mirrored TxB(2) formation in this patient, portraying a functional ability of the platelet to aggregate within 24h of aspirin ingestion. COX-independent platelet aggregation triggered TxA(2) production to a similar extent in all patients, likely through signal-dependent protein synthesis.CONCLUSIONSCOX-dependent platelet activity is recovered in certain individuals within 24h of aspirin administration. Further research should consider increasing aspirin dosing frequency to twice daily, to allow sustained inhibition in such subjects. |
Author | Lordkipanidzé, Marie Schampaert, Erick Diodati, Jean G Palisaitis, Donald A Pharand, Chantal |
Author_xml | – sequence: 1 fullname: Lordkipanidzé, Marie – sequence: 2 fullname: Pharand, Chantal – sequence: 3 fullname: Schampaert, Erick – sequence: 4 fullname: Palisaitis, Donald A – sequence: 5 fullname: Diodati, Jean G |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24366248$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20207433$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU2LFDEQhoPs4s6u_gORvoinHpN0vvoiyLK6woKH3T14Ckm6RtP2JGPSI_a_t4YZFbwIBQVVz1tVvHVJzlJOQMgLRteMMvVmXMcxuDKsOcUS5RjyCVkxo0XLtBRnZIWYbiXX3QW5rHWklIq-N0_JBaecatF1K_L5FmYo-QskiPPSxNTsJjfDBHMTljDl_HPBnquAra_Rxznm1PilcXUXC9IYIZecXMFawVFLM8QKKHhGzjduqvD8lK_I4_ubh-vb9u7Th4_X7-7aIISaWx_8RnmutaSKc2-8Aj5I2StjODU-OOUYuKEPwIQKg5IGE6dCCg0yAO-uyOvj3F3J3_dQZ7uNNcA0uQR5X63RUnNOux5JcSRDybUW2NhdiVu83DJqD57a0R49tQdPLeUYEmUvTwv2fgvDH9FvExF4dQJcDW7aFJdCrH850SnFhUHu7ZEDtONHhGJriJACDLFAmO2Q4_8u-XdAmGKKuPMbLFDHvC8JrbbMVhTY-8P_D-9n-Hnac9X9As6nrk8 |
CODEN | IJCDD5 |
CitedBy_id | crossref_primary_10_3109_09537104_2012_711865 crossref_primary_10_1002_cpt_438 crossref_primary_10_3109_10408363_2012_731377 crossref_primary_10_3310_hta19370 crossref_primary_10_1055_a_2170_1892 crossref_primary_10_1016_j_medcli_2013_09_034 crossref_primary_10_1016_j_ijcard_2014_05_013 crossref_primary_10_1080_14779072_2016_1247693 crossref_primary_10_1186_s13643_015_0078_3 crossref_primary_10_4103_jpcs_jpcs_46_22 crossref_primary_10_1160_TH15_05_0430 crossref_primary_10_1080_09537104_2018_1478402 crossref_primary_10_1155_2012_376721 crossref_primary_10_3390_ijms222313079 crossref_primary_10_1111_j_1538_7836_2012_04764_x crossref_primary_10_1055_s_0041_1731309 crossref_primary_10_1111_j_1538_7836_2012_04723_x crossref_primary_10_1586_erc_12_144 crossref_primary_10_1016_j_thromres_2016_11_018 crossref_primary_10_1080_14779072_2016_1188005 crossref_primary_10_1177_0194599815573702 crossref_primary_10_1177_1479164112441486 |
Cites_doi | 10.1016/j.thromres.2007.12.011 10.1093/eurheartj/ehm226 10.1016/0002-9149(91)90379-Y 10.1161/01.RES.0000214553.37930.3e 10.1161/01.CIR.101.10.1206 10.1136/jcp.2004.022129 10.1016/j.ahj.2006.10.040 10.1161/ATVBAHA.107.160218 10.1161/01.CIR.0000147228.29325.F9 10.1073/pnas.112202999 10.1016/j.jacc.2008.05.031 10.1016/j.amjcard.2006.09.011 10.1111/j.1538-7836.2008.03211.x 10.1080/09537100500441101 10.1074/mcp.M300063-MCP200 10.1016/j.cell.2005.06.015 10.1161/01.CIR.0000081770.51929.5A 10.1001/archinte.167.15.1593 10.1161/01.ATV.0000145980.39477.a9 10.1160/TH05-10-0649 10.1016/j.jacc.2005.06.058 10.1016/j.pharmthera.2006.05.011 10.1111/j.1538-7836.2006.02245.x 10.1136/hrt.2008.150631 10.1136/bmj.324.7329.71 10.1080/00365510701601673 10.1016/j.ijcard.2008.11.048 10.1111/j.1538-7836.2007.02387.x 10.1160/TH05-10-0653 |
ContentType | Journal Article |
Copyright | Elsevier Ireland Ltd 2010 Elsevier Ireland Ltd 2015 INIST-CNRS Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
Copyright_xml | – notice: Elsevier Ireland Ltd – notice: 2010 Elsevier Ireland Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.ijcard.2010.02.025 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1874-1754 |
EndPage | 44 |
ExternalDocumentID | 10_1016_j_ijcard_2010_02_025 20207433 24366248 S0167527310000926 1_s2_0_S0167527310000926 |
Genre | Comparative Study Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 0R 0SF 1 1- 1B1 1P 1RT 1~. 1~5 29J 4.4 457 4G. 53G 55 5GY 5RE 5VS 7-5 71M 8P 9JM AABNK AACTN AAEDT AAIAV AAIKJ AAKOC AALMO AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFLS ABFNM ABLJU ABLVK ABMAC ABMZM ABOCM ABPIF ABPTK ABWYI ABXDB ABYKQ ACDAQ ACGFS ACIUM ACRLP ADALY ADBBV ADEZE AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FO G- G-2 G-Q GBLVA GJ HEB HMK HMO HVGLF HZ IHE IPNFZ J1W K KOM LCYCR M M29 M41 MO0 N9A NCXOZ O-L O9- OA. OAUVE OL OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SEL SES SEW SPCBC SSH SSZ T5K UV1 WUQ X7M Z5R ZA5 ZGI --- --K --M .1- .55 .FO .GJ .~1 0R~ 1P~ 8P~ AAEDW ABJNI ADMUD AHPSJ AXJTR EFLBG FYGXN HZ~ OL~ ~G- AAUGY IQODW AAXKI AKRWK CGR CUY CVF ECM EIF NPM AAYXX ADVLN AFJKZ CITATION 7X8 |
ID | FETCH-LOGICAL-c446t-bcbf6b27750622b8b6e2d559688208bca6a1ead9ce146cd65846c204547e5ce23 |
IEDL.DBID | .~1 |
ISSN | 0167-5273 |
IngestDate | Fri Aug 16 11:27:34 EDT 2024 Thu Sep 26 19:14:59 EDT 2024 Sat Sep 28 07:47:10 EDT 2024 Sun Oct 22 16:09:57 EDT 2023 Fri Feb 23 02:29:18 EST 2024 Thu Aug 18 18:36:06 EDT 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Aspirin Cyclooxygenase Platelet aggregation Thromboxane Coronary artery disease Prostaglandin-endoperoxide synthase Enzyme Cardiovascular disease Acetylsalicylic acid Coronary heart disease Heterogeneity Platelet Oxidoreductases Inhibition Cardiology |
Language | English |
License | CC BY 4.0 Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c446t-bcbf6b27750622b8b6e2d559688208bca6a1ead9ce146cd65846c204547e5ce23 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 20207433 |
PQID | 875722039 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_875722039 crossref_primary_10_1016_j_ijcard_2010_02_025 pubmed_primary_20207433 pascalfrancis_primary_24366248 elsevier_sciencedirect_doi_10_1016_j_ijcard_2010_02_025 elsevier_clinicalkeyesjournals_1_s2_0_S0167527310000926 |
PublicationCentury | 2000 |
PublicationDate | 2011-07-01 |
PublicationDateYYYYMMDD | 2011-07-01 |
PublicationDate_xml | – month: 07 year: 2011 text: 2011-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Shannon |
PublicationPlace_xml | – name: Shannon – name: Netherlands |
PublicationTitle | International journal of cardiology |
PublicationTitleAlternate | Int J Cardiol |
PublicationYear | 2011 |
Publisher | Elsevier Ireland Ltd Elsevier |
Publisher_xml | – name: Elsevier Ireland Ltd – name: Elsevier |
References | Guthikonda, Alviar, Vaduganathan, Arikan, Tellez, DeLao (bb0120) 2008; 52 Weyrich, Schwertz, Kraiss, Zimmerman (bb0030) 2009; 7 Zimmerman, Weyrich (bb0135) 2008; 28 FitzGerald (bb0040) 1991; 68 Maree, Curtin, Dooley, Conroy, Crean, Cox (bb0070) 2005; 46 Hovens, Snoep, Eikenboom, van der Bom, Mertens, Huisman (bb0075) 2007; 153 Muir, Patterson, McMullin, McKeown (bb0140) 2009; 95 Michelson (bb0045) 2004; 110 Cornelissen, Kirtland, Lim, Goddard, Bellm, Sheridan (bb0060) 2006; 95 Vilahur, Choi, Zafar, Viles-Gonzalez, Vorchheimer, Fuster (bb0125) 2007; 5 Kranzhofer, Ruef (bb0100) 2006; 17 Bracey, Grigore, Nussmeier (bb0015) 2006; 98 Denis, Tolley, Bunting, Schwertz, Jiang, Lindemann (bb0025) 2005; 122 Riondino, Trifiro, Principessa, Mascioletti, Di Renzo, Gaudio (bb0055) 2008; 122 Perneby, Wallen, Rooney, Fitzgerald, Hjemdahl (bb0130) 2006; 95 Rocca, Secchiero, Ciabattoni, Ranelletti, Catani, Guidotti (bb0095) 2002; 99 Mani, Luxembourg, Klaffling, Erbe, Lindhoff-Last (bb0050) 2005; 58 Meen, Brosstad, Khiabani, Gjertsen, Lauritsen, Pedersen (bb0065) 2008; 68 Zimmermann, Wenk, Kim, Kienzle, Weber, Gams (bb0105) 2003; 108 McRedmond, Park, Reilly, Coppinger, Maguire, Shields (bb0020) 2004; 3 Coats (bb0150) 2009; 131 Antithrombotic Trialists' Collaboration (bb0005) 2002; 324 Lordkipanidzé, Pharand, Schampaert, Turgeon, Palisaitis, Diodati (bb0080) 2007; 28 Lordkipanidzé, Diodati, Turgeon, Schampaert, Palisaitis, Pharand (bb0115) 2009 Evangelista, Manarini, Di Santo, Capone, Ricciotti, Di Francesco (bb0035) 2006; 98 Cattaneo (bb0085) 2004; 24 Awtry, Loscalzo (bb0010) 2000; 101 Guthikonda, Lev, Patel, Delao, Bergeron, Dong (bb0110) 2007; 5 Lordkipanidzé, Pharand, Palisaitis, Diodati (bb0090) 2006; 112 Snoep, Hovens, Eikenboom, van der Bom, Huisman (bb0145) 2007; 167 Kranzhofer (10.1016/j.ijcard.2010.02.025_bb0100) 2006; 17 Zimmermann (10.1016/j.ijcard.2010.02.025_bb0105) 2003; 108 Guthikonda (10.1016/j.ijcard.2010.02.025_bb0120) 2008; 52 Evangelista (10.1016/j.ijcard.2010.02.025_bb0035) 2006; 98 Hovens (10.1016/j.ijcard.2010.02.025_bb0075) 2007; 153 Lordkipanidzé (10.1016/j.ijcard.2010.02.025_bb0080) 2007; 28 Lordkipanidzé (10.1016/j.ijcard.2010.02.025_bb0090) 2006; 112 Lordkipanidzé (10.1016/j.ijcard.2010.02.025_bb0115) 2009 Antithrombotic Trialists' Collaboration (10.1016/j.ijcard.2010.02.025_bb0005) 2002; 324 Denis (10.1016/j.ijcard.2010.02.025_bb0025) 2005; 122 Zimmerman (10.1016/j.ijcard.2010.02.025_bb0135) 2008; 28 Michelson (10.1016/j.ijcard.2010.02.025_bb0045) 2004; 110 Vilahur (10.1016/j.ijcard.2010.02.025_bb0125) 2007; 5 Coats (10.1016/j.ijcard.2010.02.025_bb0150) 2009; 131 Maree (10.1016/j.ijcard.2010.02.025_bb0070) 2005; 46 Cornelissen (10.1016/j.ijcard.2010.02.025_bb0060) 2006; 95 Riondino (10.1016/j.ijcard.2010.02.025_bb0055) 2008; 122 Awtry (10.1016/j.ijcard.2010.02.025_bb0010) 2000; 101 Meen (10.1016/j.ijcard.2010.02.025_bb0065) 2008; 68 Bracey (10.1016/j.ijcard.2010.02.025_bb0015) 2006; 98 FitzGerald (10.1016/j.ijcard.2010.02.025_bb0040) 1991; 68 Cattaneo (10.1016/j.ijcard.2010.02.025_bb0085) 2004; 24 Mani (10.1016/j.ijcard.2010.02.025_bb0050) 2005; 58 McRedmond (10.1016/j.ijcard.2010.02.025_bb0020) 2004; 3 Rocca (10.1016/j.ijcard.2010.02.025_bb0095) 2002; 99 Perneby (10.1016/j.ijcard.2010.02.025_bb0130) 2006; 95 Muir (10.1016/j.ijcard.2010.02.025_bb0140) 2009; 95 Weyrich (10.1016/j.ijcard.2010.02.025_bb0030) 2009; 7 Snoep (10.1016/j.ijcard.2010.02.025_bb0145) 2007; 167 Guthikonda (10.1016/j.ijcard.2010.02.025_bb0110) 2007; 5 |
References_xml | – volume: 68 start-page: 11B year: 1991 end-page: 15B ident: bb0040 article-title: Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists publication-title: Am J Cardiol contributor: fullname: FitzGerald – volume: 68 start-page: 185 year: 2008 end-page: 191 ident: bb0065 article-title: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography publication-title: Scand J Clin Lab Invest contributor: fullname: Pedersen – volume: 112 start-page: 733 year: 2006 end-page: 743 ident: bb0090 article-title: Aspirin resistance: truth or dare publication-title: Pharmacol Ther contributor: fullname: Diodati – volume: 28 start-page: 1702 year: 2007 end-page: 1708 ident: bb0080 article-title: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease publication-title: Eur Heart J contributor: fullname: Diodati – volume: 98 start-page: 25N year: 2006 end-page: 32N ident: bb0015 article-title: Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures publication-title: Am J Cardiol contributor: fullname: Nussmeier – volume: 324 start-page: 71 year: 2002 end-page: 86 ident: bb0005 article-title: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients publication-title: BMJ contributor: fullname: Antithrombotic Trialists' Collaboration – volume: 122 start-page: 359 year: 2008 end-page: 365 ident: bb0055 article-title: Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production publication-title: Thromb Res contributor: fullname: Gaudio – volume: 52 start-page: 743 year: 2008 end-page: 749 ident: bb0120 article-title: Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease publication-title: J Am Coll Cardiol contributor: fullname: DeLao – volume: 99 start-page: 7634 year: 2002 end-page: 7639 ident: bb0095 article-title: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets publication-title: PNAS contributor: fullname: Guidotti – volume: 122 start-page: 379 year: 2005 end-page: 391 ident: bb0025 article-title: Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets publication-title: Cell contributor: fullname: Lindemann – volume: 95 start-page: 476 year: 2006 end-page: 482 ident: bb0060 article-title: Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function publication-title: Thromb Haemost contributor: fullname: Sheridan – volume: 5 start-page: 490 year: 2007 end-page: 496 ident: bb0110 article-title: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin publication-title: J Thromb Haemost contributor: fullname: Dong – volume: 3 start-page: 133 year: 2004 end-page: 144 ident: bb0020 article-title: Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes publication-title: Mol Cell Proteomics contributor: fullname: Shields – volume: 95 start-page: 1225 year: 2009 end-page: 1229 ident: bb0140 article-title: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease publication-title: Heart contributor: fullname: McKeown – volume: 28 start-page: s17 year: 2008 end-page: s24 ident: bb0135 article-title: Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Weyrich – volume: 58 start-page: 747 year: 2005 end-page: 750 ident: bb0050 article-title: Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements publication-title: J Clin Pathol contributor: fullname: Lindhoff-Last – volume: 46 start-page: 1258 year: 2005 end-page: 1263 ident: bb0070 article-title: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease publication-title: J Am Coll Cardiol contributor: fullname: Cox – volume: 5 start-page: 82 year: 2007 end-page: 90 ident: bb0125 article-title: Normalization of platelet reactivity in clopidogrel-treated subjects publication-title: J Thromb Haemost contributor: fullname: Fuster – volume: 95 start-page: 652 year: 2006 end-page: 658 ident: bb0130 article-title: Dose- and time-dependent antiplatelet effects of aspirin publication-title: Thromb Haemost contributor: fullname: Hjemdahl – volume: 17 start-page: 163 year: 2006 end-page: 169 ident: bb0100 article-title: Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism publication-title: Platelets contributor: fullname: Ruef – volume: 167 start-page: 1593 year: 2007 end-page: 1599 ident: bb0145 article-title: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis publication-title: Arch Intern Med contributor: fullname: Huisman – volume: 24 start-page: 1980 year: 2004 end-page: 1987 ident: bb0085 article-title: Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance publication-title: Arterioscler Thromb Vasc Biol contributor: fullname: Cattaneo – volume: 101 start-page: 1206 year: 2000 end-page: 1218 ident: bb0010 article-title: Aspirin publication-title: Circulation contributor: fullname: Loscalzo – volume: 98 start-page: 593 year: 2006 end-page: 595 ident: bb0035 article-title: De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin publication-title: Circ Res contributor: fullname: Di Francesco – volume: 110 start-page: e489 year: 2004 end-page: e493 ident: bb0045 article-title: Platelet function testing in cardiovascular diseases publication-title: Circulation contributor: fullname: Michelson – volume: 153 start-page: 175 year: 2007 end-page: 181 ident: bb0075 article-title: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review publication-title: Am Heart J contributor: fullname: Huisman – volume: 131 start-page: 149 year: 2009 end-page: 150 ident: bb0150 article-title: Ethical authorship and publishing publication-title: Int J Cardiol contributor: fullname: Coats – volume: 108 start-page: 542 year: 2003 end-page: 547 ident: bb0105 article-title: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery publication-title: Circulation contributor: fullname: Gams – volume: 7 start-page: 241 year: 2009 end-page: 246 ident: bb0030 article-title: Protein synthesis by platelets: historical and new perspectives publication-title: J Thromb Haemost contributor: fullname: Zimmerman – year: 2009 ident: bb0115 article-title: Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin publication-title: Int J Cardiol contributor: fullname: Pharand – volume: 122 start-page: 359 year: 2008 ident: 10.1016/j.ijcard.2010.02.025_bb0055 article-title: Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production publication-title: Thromb Res doi: 10.1016/j.thromres.2007.12.011 contributor: fullname: Riondino – volume: 28 start-page: 1702 year: 2007 ident: 10.1016/j.ijcard.2010.02.025_bb0080 article-title: A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease publication-title: Eur Heart J doi: 10.1093/eurheartj/ehm226 contributor: fullname: Lordkipanidzé – volume: 68 start-page: 11B year: 1991 ident: 10.1016/j.ijcard.2010.02.025_bb0040 article-title: Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists publication-title: Am J Cardiol doi: 10.1016/0002-9149(91)90379-Y contributor: fullname: FitzGerald – volume: 98 start-page: 593 year: 2006 ident: 10.1016/j.ijcard.2010.02.025_bb0035 article-title: De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin publication-title: Circ Res doi: 10.1161/01.RES.0000214553.37930.3e contributor: fullname: Evangelista – volume: 101 start-page: 1206 year: 2000 ident: 10.1016/j.ijcard.2010.02.025_bb0010 article-title: Aspirin publication-title: Circulation doi: 10.1161/01.CIR.101.10.1206 contributor: fullname: Awtry – volume: 58 start-page: 747 year: 2005 ident: 10.1016/j.ijcard.2010.02.025_bb0050 article-title: Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements publication-title: J Clin Pathol doi: 10.1136/jcp.2004.022129 contributor: fullname: Mani – volume: 153 start-page: 175 year: 2007 ident: 10.1016/j.ijcard.2010.02.025_bb0075 article-title: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review publication-title: Am Heart J doi: 10.1016/j.ahj.2006.10.040 contributor: fullname: Hovens – volume: 28 start-page: s17 year: 2008 ident: 10.1016/j.ijcard.2010.02.025_bb0135 article-title: Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.107.160218 contributor: fullname: Zimmerman – year: 2009 ident: 10.1016/j.ijcard.2010.02.025_bb0115 article-title: Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin publication-title: Int J Cardiol contributor: fullname: Lordkipanidzé – volume: 110 start-page: e489 year: 2004 ident: 10.1016/j.ijcard.2010.02.025_bb0045 article-title: Platelet function testing in cardiovascular diseases publication-title: Circulation doi: 10.1161/01.CIR.0000147228.29325.F9 contributor: fullname: Michelson – volume: 99 start-page: 7634 year: 2002 ident: 10.1016/j.ijcard.2010.02.025_bb0095 article-title: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets publication-title: PNAS doi: 10.1073/pnas.112202999 contributor: fullname: Rocca – volume: 52 start-page: 743 year: 2008 ident: 10.1016/j.ijcard.2010.02.025_bb0120 article-title: Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2008.05.031 contributor: fullname: Guthikonda – volume: 98 start-page: 25N year: 2006 ident: 10.1016/j.ijcard.2010.02.025_bb0015 article-title: Impact of platelet testing on presurgical screening and implications for cardiac and noncardiac surgical procedures publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2006.09.011 contributor: fullname: Bracey – volume: 7 start-page: 241 year: 2009 ident: 10.1016/j.ijcard.2010.02.025_bb0030 article-title: Protein synthesis by platelets: historical and new perspectives publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2008.03211.x contributor: fullname: Weyrich – volume: 17 start-page: 163 year: 2006 ident: 10.1016/j.ijcard.2010.02.025_bb0100 article-title: Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism publication-title: Platelets doi: 10.1080/09537100500441101 contributor: fullname: Kranzhofer – volume: 3 start-page: 133 year: 2004 ident: 10.1016/j.ijcard.2010.02.025_bb0020 article-title: Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M300063-MCP200 contributor: fullname: McRedmond – volume: 122 start-page: 379 year: 2005 ident: 10.1016/j.ijcard.2010.02.025_bb0025 article-title: Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets publication-title: Cell doi: 10.1016/j.cell.2005.06.015 contributor: fullname: Denis – volume: 108 start-page: 542 year: 2003 ident: 10.1016/j.ijcard.2010.02.025_bb0105 article-title: Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery publication-title: Circulation doi: 10.1161/01.CIR.0000081770.51929.5A contributor: fullname: Zimmermann – volume: 167 start-page: 1593 year: 2007 ident: 10.1016/j.ijcard.2010.02.025_bb0145 article-title: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis publication-title: Arch Intern Med doi: 10.1001/archinte.167.15.1593 contributor: fullname: Snoep – volume: 24 start-page: 1980 year: 2004 ident: 10.1016/j.ijcard.2010.02.025_bb0085 article-title: Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000145980.39477.a9 contributor: fullname: Cattaneo – volume: 95 start-page: 476 year: 2006 ident: 10.1016/j.ijcard.2010.02.025_bb0060 article-title: Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function publication-title: Thromb Haemost doi: 10.1160/TH05-10-0649 contributor: fullname: Cornelissen – volume: 46 start-page: 1258 year: 2005 ident: 10.1016/j.ijcard.2010.02.025_bb0070 article-title: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.06.058 contributor: fullname: Maree – volume: 112 start-page: 733 year: 2006 ident: 10.1016/j.ijcard.2010.02.025_bb0090 article-title: Aspirin resistance: truth or dare publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2006.05.011 contributor: fullname: Lordkipanidzé – volume: 5 start-page: 82 year: 2007 ident: 10.1016/j.ijcard.2010.02.025_bb0125 article-title: Normalization of platelet reactivity in clopidogrel-treated subjects publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.02245.x contributor: fullname: Vilahur – volume: 95 start-page: 1225 year: 2009 ident: 10.1016/j.ijcard.2010.02.025_bb0140 article-title: Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease publication-title: Heart doi: 10.1136/hrt.2008.150631 contributor: fullname: Muir – volume: 324 start-page: 71 year: 2002 ident: 10.1016/j.ijcard.2010.02.025_bb0005 article-title: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients publication-title: BMJ doi: 10.1136/bmj.324.7329.71 contributor: fullname: Antithrombotic Trialists' Collaboration – volume: 68 start-page: 185 year: 2008 ident: 10.1016/j.ijcard.2010.02.025_bb0065 article-title: No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography publication-title: Scand J Clin Lab Invest doi: 10.1080/00365510701601673 contributor: fullname: Meen – volume: 131 start-page: 149 year: 2009 ident: 10.1016/j.ijcard.2010.02.025_bb0150 article-title: Ethical authorship and publishing publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2008.11.048 contributor: fullname: Coats – volume: 5 start-page: 490 year: 2007 ident: 10.1016/j.ijcard.2010.02.025_bb0110 article-title: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2007.02387.x contributor: fullname: Guthikonda – volume: 95 start-page: 652 year: 2006 ident: 10.1016/j.ijcard.2010.02.025_bb0130 article-title: Dose- and time-dependent antiplatelet effects of aspirin publication-title: Thromb Haemost doi: 10.1160/TH05-10-0653 contributor: fullname: Perneby |
SSID | ssj0004998 |
Score | 2.1542106 |
Snippet | Abstract Background Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme... Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been... Platelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has been... BACKGROUNDPlatelets, long believed to be incapable of de novo protein synthesis, may retain their ability to form the cyclooxygenase (COX) enzyme once it has... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 39 |
SubjectTerms | Adult Aspirin Aspirin - pharmacology Aspirin - therapeutic use Biological and medical sciences Cardiology. Vascular system Cardiovascular Coronary artery disease Coronary Artery Disease - drug therapy Coronary Artery Disease - enzymology Coronary heart disease Cyclooxygenase Cyclooxygenase Inhibitors - pharmacology Cyclooxygenase Inhibitors - therapeutic use Female Genetic Heterogeneity - drug effects Heart Humans Male Medical sciences Middle Aged Platelet aggregation Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Prostaglandin-Endoperoxide Synthases - metabolism Thromboxane Thromboxane A2 - antagonists & inhibitors Thromboxane A2 - metabolism Thromboxane B2 - antagonists & inhibitors Thromboxane B2 - metabolism |
Title | Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0167527310000926 https://dx.doi.org/10.1016/j.ijcard.2010.02.025 https://www.ncbi.nlm.nih.gov/pubmed/20207433 https://search.proquest.com/docview/875722039 |
Volume | 150 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS-wwEB5EQYSDeDke18uSh_Nat5umafMoi7JekaOCPoUkTbEi7WJXcF_87U7a1AsHEYRAoUlpmJnMfEm-TAD-ZhgjbJornKYmOmDC5IFK0igIc56ZKI1z0SR7Pjvn42t2fBPfzMGoOwvjaJXe97c-vfHW_s3AS3MwKYrBpSPQu_RhzQq1oC7tNsNghDa99_JO80BEn3b5vV3r7vhcw_Eq7g3qwRO8KJb4q_D0a6JqFFre3nbxNRxtwtLhCix7PEn22y6vwpwt12DxzO-Yr8Pt2PFdKjQTi3ibFCWZPCC8RG0RMzMPVfU8wzoMZVh1V-iGwEX0jCi3A4-tsRiX5EA94jtH_5wRv6fzG64PD65G48BfpxAYnPNNA210zjVNECNwSnWquaUZTig4guww1UZxNUS7Esai9zRZA02My1bPEhsbS6MNmC-r0m4CYVESZtQonYiYWaV0JkSu1DBnQiVU0x4EnRTlpM2aITs62b1spS6d1GVIscQ9SDpRy-5EKPowW_sBVcuhrLGl_E_pH7_8ZDcSQ8I3_-x_0ulbRymLOKcs7QHplCxxzLmNFFXa6qmW7hIASsNI9OBPq_z3jxF-IyiLtn7cr21YatetHSV4B-anj092F4HPVPcby-7Dwv7o3-mFex6djM9fAeryBL4 |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB7SDbSBEvrO9pHq0KtZryxL1jGEBqfJ7qUJpCchyTJ1CPYSbyD77zOS5aahhEBBJ1nCYkaa-aT5NAL4VqGPcEWtcZsqTMKkrRMtiixJa17ZrMhrGZI9L5a8PGc_LvKLLTgc78J4WmW0_YNND9Y61syiNGerppn99AR6nz4snFBLyp_BNsvFnE1g--D4pFzeX4-U4UnckOLbdxhv0AWaV3NpURWR40Wx5I95qJcr3aPc6uHBi8cRafBMR69gN0JKcjCM-jVsufYNPF_EoPlb-FV6ykuHM8Uh5CZNS1ZXiDBRYcRu7FXX3W7wG3oz_PS7MYHDRcyGaB-Ex9ZYrM9zoK-xzjNANySGdd7B-dH3s8MyiS8qJBa3fevEWFNzQwXCBE6pKQx3tMI9BUecnRbGaq7nOLWkdWhAbRXQifUJ65lwuXU0ew-TtmvdHhCWibSiVhshc-a0NpWUtdbzmkktqKFTSEYpqtWQOEONjLJLNUhdeamrlGLJpyBGUavxUiiaMdfHNdWrueqxpfpH73_3fDB1FHqFJ_65_0CnfwZKWcY5ZcUUyKhkhcvOx1J067qbXvl3AChNMzmFD4Py7zsjAkdcln3873F9hRfl2eJUnR4vTz7BznCM7RnCn2Gyvr5xXxAHrc1-nOd3tAkF3w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heterogeneity+in+platelet+cyclooxygenase+inhibition+by+aspirin+in+coronary+artery+disease&rft.jtitle=International+journal+of+cardiology&rft.au=Lordkipanidz%C3%A9%2C+Marie&rft.au=Pharand%2C+Chantal&rft.au=Schampaert%2C+Erick&rft.au=Palisaitis%2C+Donald+A.&rft.date=2011-07-01&rft.pub=Elsevier+Ireland+Ltd&rft.issn=0167-5273&rft.eissn=1874-1754&rft.volume=150&rft.issue=1&rft.spage=39&rft.epage=44&rft_id=info:doi/10.1016%2Fj.ijcard.2010.02.025&rft.externalDocID=S0167527310000926 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01675273%2FS0167527311X0013X%2Fcov150h.gif |